AGTC President & CEO to Present at Cantor Healthcare Conference on July 8, 2015

GAINESVILLE, Fla., July 6, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO will present at the Cantor Fitzgerald Healthcare Conference on July 8, 2015 at 10:15am in New York. Ms. Washer will provide a corporate overview and will discuss key corporate milestones related to AGTC's lead development programs, including X-linked retinoschisis (XLRS), achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

A live audio webcast of the presentation will be accessible by visiting ir.agtc.com/events.cfm. A replay will be available on AGTC's website for at least 30 days following the event.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also using its gene therapy expertise to expand into disease indications with large market opportunity such as wet AMD.

About X-linked Retinoschisis (XLRS)

XLRS is an inherited retinal disease caused by mutations in the RS1 gene, which encodes the retinoschisin protein. It is characterized by abnormal splitting of the layers of the retina, resulting in poor visual acuity in young boys, which can progress to legal blindness in adult men.

About Achromatopsia (ACHM)

ACHM is an inherited retinal disease, which is present from birth and is characterized by the lack of cone photoreceptor function. The condition results in markedly reduced visual acuity light sensitivity causing day blindness, and complete loss of color discrimination. Best-corrected visual acuity in persons affected by ACHM, even under subdued light conditions, is usually about 20/200, a level at which people are considered legally blind.

About X-linked Retinitis Pigmentosa (XLRP)

XLRP is an inherited condition that causes boys to develop night blindness by the time they are ten and progresses to legal blindness by their early forties.

CONTACT: David Carey
         Lazar Partners Ltd.
         T: (212) 867-1768
         [email protected]

         Corporate Contact:

         Larry Bullock
         Chief Financial Officer
         Applied Genetic Technologies Corporation
         T: (386) 462-2204
         [email protected]

Source: Applied Genetic Technologies

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Empowering Female Voices: GAGA Calls on Women Worldwide for Support Meme
• Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Luna, and HireRight Innovations and Encourages Investors to Contact the Firm
• Churchwell Insurance Agency's Executive Liability Team Recognized as Industry Leaders at Water Tower Research AI and Technology Hybrid Conference